{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:11:11Z","timestamp":1780369871905,"version":"3.54.1"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China Scholarship Council PhD fellowship","award":["202106370032"],"award-info":[{"award-number":["202106370032"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Stem cell therapies hold promise for halting or reversing kidney disease and improving kidney transplant (KTx) outcomes. One route to large-scale clinical application of stem cell therapies for kidney disease is through their capacity to modulate the balance between tissue injury and repair via crosstalk with other cells. Among the key disease-modulating effects of stem cells is their interaction with components of the immune system involved in harmful inflammation during acute kidney injury (AKI), chronic kidney disease (CKD) and complications of KTx. Extensive basic research demonstrates that stem cells employ diverse paracrine mechanisms to re-program immunological activities from pro-inflammatory\/pro-fibrotic to anti-inflammatory\/pro-repair. The therapeutic benefits of these effects are confirmed in many pre-clinical models of AKI, CKD and KTx for autologous and allogeneic stem cells including hematopoietic stem cells, mesenchymal stem cells, renal progenitor cells, and induced pluripotent stem cells. Nonetheless, translating these findings into therapeutic immunomodulatory cell products that improve the lives of those with kidney disease is highly challenging. The aims of this review are to: (a) Summarize recent insights into the common molecular and cellular mechanisms of immune-mediated tissue injury in kidney disease and KTx along with the types of stem therapies that have been developed to address them. (b) Critically evaluate the extent to which clinical trials of stem cell products have validated such effects in humans with kidney disease and KTx. (c) Identify key bottlenecks to the large-scale application of stem cell therapies to reduce the burden of kidney disease on patients and societies.<\/jats:p>","DOI":"10.1093\/stmcls\/sxag015","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:45:35Z","timestamp":1774442735000},"source":"Crossref","is-referenced-by-count":1,"title":["Stem cell therapies to modulate harmful immune responses in kidney disease: progress toward clinical validation"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-2543","authenticated-orcid":false,"given":"Qifeng","family":"Ou","sequence":"first","affiliation":[{"name":"Regenerative Medicine Institute (REMEDI) at C\u00daRAM Research Ireland Centre for Medical Devices, University of Galway , Galway,","place":["Ireland"]},{"name":"Department of Hand and Microsurgery, Xiangya Hospital, Central South University , Changsha,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical University , Shijiazhuang,","place":["China"]},{"name":"Joint Stem Cell Research Center, Hebei Medical University-University of Galway, Hebei Medical University , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengkun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical University , Shijiazhuang,","place":["China"]},{"name":"Joint Stem Cell Research Center, Hebei Medical University-University of Galway, Hebei Medical University , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical University , Shijiazhuang,","place":["China"]},{"name":"Joint Stem Cell Research Center, Hebei Medical University-University of Galway, Hebei Medical University , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiqing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical University , Shijiazhuang,","place":["China"]},{"name":"Joint Stem Cell Research Center, Hebei Medical University-University of Galway, Hebei Medical University , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-8056","authenticated-orcid":false,"given":"Matthew D","family":"Griffin","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Institute (REMEDI) at C\u00daRAM Research Ireland Centre for Medical Devices, University of Galway , Galway,","place":["Ireland"]},{"name":"Joint Stem Cell Research Center, Hebei Medical University-University of Galway, Hebei Medical University , Shijiazhuang,","place":["China"]},{"name":"Discipline of Advanced Therapies, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway , Galway,","place":["Ireland"]},{"name":"Clinical Trials Institute, University of Galway , Galway,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"2026052423463769400_sxag015-B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41572-024-00589-9","article-title":"Chronic kidney disease","volume":"11","author":"Romagnani","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026052423463769400_sxag015-B2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.kint.2022.02.023","article-title":"Kidney repair and regeneration: perspectives of the NIDDK (re)building a kidney consortium","volume":"101","author":"Naved","year":"2022","journal-title":"Kidney Int"},{"key":"2026052423463769400_sxag015-B3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/rme.09.74","article-title":"Stem cell paracrine actions and tissue regeneration","volume":"5","author":"Baraniak","year":"2010","journal-title":"Regen Med"},{"key":"2026052423463769400_sxag015-B4","doi-asserted-by":"publisher","first-page":"954574","DOI":"10.3389\/fmed.2022.954574","article-title":"Interaction between intrinsic renal cells and immune cells in the progression of acute kidney injury","volume":"9","author":"Deng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026052423463769400_sxag015-B5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1681\/ASN.2017070800","article-title":"Four-dimensional imaging of T cells in kidney transplant rejection","volume":"29","author":"Hughes","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41581-025-00958-x","article-title":"Innate immune cells in acute and chronic kidney disease","volume":"21","author":"Meng","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2026052423463769400_sxag015-B7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.kint.2021.11.029","article-title":"Allorecognition and the spectrum of kidney transplant rejection","volume":"101","author":"Callemeyn","year":"2022","journal-title":"Kidney Int"},{"key":"2026052423463769400_sxag015-B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00467-024-06514-2","article-title":"Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases","volume":"40","author":"Ho","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2026052423463769400_sxag015-B9","doi-asserted-by":"publisher","first-page":"1287465","DOI":"10.3389\/fimmu.2023.1287465","article-title":"Revisiting regulatory T cells as modulators of innate immune response and inflammatory diseases","volume":"14","author":"Ou","year":"2023","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026052423463769400_sxag015-B11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026052423463769400_sxag015-B12","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1681\/ASN.2020060806","article-title":"Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease","volume":"31","author":"Conway","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fimmu.2019.00587","article-title":"Natural killer cells in kidney health and disease","volume":"10","author":"Turner","year":"2019","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B14","doi-asserted-by":"publisher","first-page":"1084448","DOI":"10.3389\/fimmu.2023.1084448","article-title":"T cells and their products in diabetic kidney disease","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/TP.0000000000005187","article-title":"Chronic rejection after kidney transplantation","volume":"109","author":"Diebold","year":"2025","journal-title":"Transplantation"},{"key":"2026052423463769400_sxag015-B16","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"2026052423463769400_sxag015-B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131552","article-title":"Urinary cell transcriptomics and acute rejection in human kidney allografts","volume":"5","author":"Verma","year":"2020","journal-title":"JCI Insight"},{"key":"2026052423463769400_sxag015-B18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/TP.0000000000004762","article-title":"Sequencing of physically interacting cells in human kidney allograft rejection to infer contact-dependent immune cell transcription","volume":"108","author":"Leckie-Harre","year":"2024","journal-title":"Transplantation"},{"key":"2026052423463769400_sxag015-B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejphar.2017.12.016","article-title":"Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets","volume":"820","author":"Lv","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"2026052423463769400_sxag015-B20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026052423463769400_sxag015-B21","doi-asserted-by":"publisher","first-page":"e03691","DOI":"10.1002\/advs.202503691","article-title":"Single cell and spatial transcriptomics define a proinflammatory and profibrotic niche after kidney injury","volume":"13","author":"Li","year":"2026","journal-title":"Adv Sci"},{"key":"2026052423463769400_sxag015-B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"2026052423463769400_sxag015-B23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","article-title":"An atlas of healthy and injured cell states and niches in the human kidney","volume":"619","author":"Lake","year":"2023","journal-title":"Nature"},{"key":"2026052423463769400_sxag015-B24","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1038\/s41467-025-62599-9","article-title":"Multimodal spatial transcriptomic characterization of mouse kidney injury and repair","volume":"16","author":"Xuanyuan","year":"2025","journal-title":"Nat Commun"},{"key":"2026052423463769400_sxag015-B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156876","article-title":"Siglec-F\u2013expressing neutrophils are essential for creating a profibrotic microenvironment in renal fibrosis","volume":"132","author":"Ryu","year":"2022","journal-title":"Journal of Clinical Investigation"},{"key":"2026052423463769400_sxag015-B26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1189\/jlb.1012512","article-title":"Macrophage phenotypes during tissue repair","volume":"93","author":"Novak","year":"2013","journal-title":"J Leukoc Biol"},{"key":"2026052423463769400_sxag015-B27","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.cmet.2022.09.026","article-title":"Comprehensive single-cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis","volume":"34","author":"Li","year":"2022","journal-title":"Cell Metab"},{"key":"2026052423463769400_sxag015-B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41581-024-00889-z","article-title":"Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease","volume":"21","author":"Miguel","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2026052423463769400_sxag015-B29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (the ONE study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"2026052423463769400_sxag015-B30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.34067\/KID.0005692020","article-title":"Progress toward the clinical application of mesenchymal stromal cells and other disease-modulating regenerative therapies: examples from the field of nephrology","volume":"2","author":"Hickson","year":"2021","journal-title":"Kidney360"},{"key":"2026052423463769400_sxag015-B31","doi-asserted-by":"publisher","first-page":"796456","DOI":"10.3389\/fimmu.2022.796456","article-title":"Successful induction of specific immunological tolerance by combined kidney and hematopoietic stem cell transplantation in HLA-Identical siblings","volume":"13","author":"Fehr","year":"2022","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa074191","article-title":"Tolerance and chimerism after renal and hematopoietic-cell transplantation","volume":"358","author":"Scandling","year":"2008","journal-title":"N Engl J Med"},{"key":"2026052423463769400_sxag015-B33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-Mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"key":"2026052423463769400_sxag015-B34","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.4252\/wjsc.v16.i12.1012","article-title":"Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34(+) cell therapy: a clinical trial","volume":"16","author":"Ohtake","year":"2024","journal-title":"World J Stem Cells"},{"key":"2026052423463769400_sxag015-B35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4252\/wjsc.v15.i4.268","article-title":"Repetitive administration of cultured human CD34+ cells improve adenine-induced kidney injury in mice","volume":"15","author":"Ohtake","year":"2023","journal-title":"World J Stem Cells"},{"key":"2026052423463769400_sxag015-B36","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/ijms20071619","article-title":"Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute\/chronic kidney disease","volume":"20","author":"Yun","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026052423463769400_sxag015-B37","doi-asserted-by":"publisher","first-page":"8658246","DOI":"10.1155\/sci\/8658246","article-title":"Narrative review of mesenchymal stem cell therapy in renal diseases: mechanisms, clinical applications, and future directions","volume":"2024","author":"Wang","year":"2024","journal-title":"Stem Cells Int."},{"key":"2026052423463769400_sxag015-B38","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/mt.2016.90","article-title":"Mesenchymal stem cells deliver exogenous MicroRNA-let7c via exosomes to attenuate renal fibrosis","volume":"24","author":"Wang","year":"2016","journal-title":"Mol Ther"},{"key":"2026052423463769400_sxag015-B39","doi-asserted-by":"publisher","first-page":"102715","DOI":"10.1016\/j.omtn.2025.102715","article-title":"miRNAs from mesenchymal-stem-cell-derived extracellular vesicles: emerging players in regenerative medicine and disease therapy","volume":"36","author":"Shahsavandi","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026052423463769400_sxag015-B40","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41577-019-0240-6","article-title":"Efferocytosis in health and disease","volume":"20","author":"Doran","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2026052423463769400_sxag015-B41","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/stem.3151","article-title":"Effects of mesenchymal stromal cells on regulatory T cells: current understanding and clinical relevance","volume":"38","author":"Negi","year":"2020","journal-title":"Stem Cells"},{"key":"2026052423463769400_sxag015-B42","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1016\/j.ymthe.2023.07.024","article-title":"Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"2026052423463769400_sxag015-B43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.stem.2025.05.008","article-title":"Hallmarks of MSCs: key quality attributes for pharmacology and clinical use","volume":"32","author":"Viswanathan","year":"2025","journal-title":"Cell Stem Cell"},{"key":"2026052423463769400_sxag015-B44","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.3390\/ijms22084178","article-title":"Localization and maintenance of engrafted mesenchymal stem cells administered via renal artery in kidneys with Ischemia-Reperfusion injury","volume":"22","author":"Yamada","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026052423463769400_sxag015-B45","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3389\/fimmu.2019.01645","article-title":"Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application","volume":"10","author":"Caplan","year":"2019","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.actbio.2025.03.042","article-title":"Arg-Gly-Asp engineered mesenchymal stem cells as targeted nanotherapeutics against kidney fibrosis by modulating m6A","volume":"198","author":"Zhang","year":"2025","journal-title":"Acta Biomater"},{"key":"2026052423463769400_sxag015-B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5620","article-title":"Innovative strategies to enhance MSCs efficacy in acute kidney injury (review)","volume":"56","author":"Zou","year":"2025","journal-title":"Int J Mol Med"},{"key":"2026052423463769400_sxag015-B48","doi-asserted-by":"publisher","first-page":"113875","DOI":"10.1016\/j.yexcr.2023.113875","article-title":"Great potential of renal progenitor cells in kidney: from the development to clinic","volume":"434","author":"Bahrami","year":"2024","journal-title":"Exp Cell Res"},{"key":"2026052423463769400_sxag015-B49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.6029","article-title":"Human scattered tubular cells represent a heterogeneous population of glycolytic dedifferentiated proximal tubule cells","volume":"259","author":"Eymael","year":"2023","journal-title":"J Pathol"},{"key":"2026052423463769400_sxag015-B50","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02266-0","article-title":"Stem\/progenitor cell in kidney: characteristics, homing, coordination, and maintenance","volume":"12","author":"Huang","year":"2021","journal-title":"Stem Cell Res Therapy"},{"key":"2026052423463769400_sxag015-B51","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf002","article-title":"Unveiling spontaneous renal tubule-like structures from human adult renal progenitor cell spheroids derived from urine","volume":"4","author":"Giannuzzi","year":"2025","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B52","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1681\/ASN.2005111228","article-title":"Kidney side population reveals multilineage potential and renal functional capacity but also cellular heterogeneity","volume":"17","author":"Challen","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B53","doi-asserted-by":"publisher","first-page":"e12009","DOI":"10.14814\/phy2.12009","article-title":"Protective effect and localization by optical imaging of human renal CD133+progenitor cells in an acute kidney injury model","volume":"2","author":"Grange","year":"2014","journal-title":"Physiol Rep"},{"key":"2026052423463769400_sxag015-B54","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/stem.1130","article-title":"Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury","volume":"30","author":"Angelotti","year":"2012","journal-title":"Stem Cells"},{"key":"2026052423463769400_sxag015-B55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/ijms22010274","article-title":"Adult renal stem\/progenitor cells can modulate T regulatory cells and double negative T cells","volume":"22","author":"Curci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026052423463769400_sxag015-B56","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/sctm.16-0352","article-title":"Human kidney-derived cells ameliorate acute kidney injury without engrafting into renal tissue","volume":"6","author":"Santeramo","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B57","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/stmcls\/sxac054","article-title":"The long non-coding RNA HOTAIR controls the self-renewal, cell senescence, and secretion of anti-aging protein \u03b1-klotho in human adult renal progenitor cells","volume":"40","author":"Picerno","year":"2022","journal-title":"Stem Cells"},{"key":"2026052423463769400_sxag015-B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1681\/ASN.2021081073","article-title":"Regrow or repair: an update on potential regenerative therapies for the kidney","volume":"33","author":"Little","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B59","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-020-02060-4","article-title":"Therapeutic potential of human induced pluripotent stem cells and renal progenitor cells in experimental chronic kidney disease","volume":"11","author":"Ribeiro","year":"2020","journal-title":"Stem Cell Research & Therapy"},{"key":"2026052423463769400_sxag015-B60","doi-asserted-by":"publisher","first-page":"8826","DOI":"10.1038\/srep08826","article-title":"Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury","volume":"5","author":"Imberti","year":"2015","journal-title":"Sci Rep"},{"key":"2026052423463769400_sxag015-B61","doi-asserted-by":"publisher","first-page":"eadt5553","DOI":"10.1126\/scitranslmed.adt5553","article-title":"Human iPSC-derived nephron progenitor cells treat acute kidney injury and chronic kidney disease in mouse models","volume":"17","author":"Araoka","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026052423463769400_sxag015-B62","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2217\/rme.15.43","article-title":"Selected renal cells modulate disease progression in rodent models of chronic kidney disease via NF-\u03baB and TGF-\u03b21 pathways","volume":"10","author":"Bruce","year":"2015","journal-title":"Regen Med"},{"key":"2026052423463769400_sxag015-B63","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.ekir.2022.04.014","article-title":"Renal autologous cell therapy to stabilize function in diabetes-related chronic kidney disease: Corroboration of mechanistic action with cell marker analysis","volume":"7","author":"Stavas","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026052423463769400_sxag015-B64","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000969","article-title":"A randomized clinical trial of kidney autologous cell therapy in diabetic kidney disease","author":"\u010ci\u017eman","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B65","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/sctm.19-0419","article-title":"A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease","volume":"10","author":"Hickson","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B66","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","article-title":"Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study","volume":"12","author":"Packham","year":"2016","journal-title":"EBioMedicine"},{"key":"2026052423463769400_sxag015-B67","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B68","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.kint.2019.11.022","article-title":"In a phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure","volume":"97","author":"Abumoawad","year":"2020","journal-title":"Kidney Int"},{"key":"2026052423463769400_sxag015-B69","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1681\/ASN.2017020151","article-title":"Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease","volume":"28","author":"Saad","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B70","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/stem.1047","article-title":"Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis","volume":"30","author":"Eirin","year":"2012","journal-title":"Stem Cells"},{"key":"2026052423463769400_sxag015-B71","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1016\/j.ekir.2025.07.042","article-title":"Intraarterial autologous mesenchymal stem cell therapy for diabetic kidney disease","volume":"10","author":"Alatta","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026052423463769400_sxag015-B72","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1111\/jcmm.17310","article-title":"Allogeneic adipose tissue-derived stem cells ELIXCYTE\u00ae in chronic kidney disease: a phase I study assessing safety and clinical feasibility","volume":"26","author":"Zheng","year":"2022","journal-title":"J Cell Mol Med"},{"key":"2026052423463769400_sxag015-B73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/stcltm\/szac080","article-title":"Safety of stromal vascular fraction cell therapy for chronic kidney disease of unknown cause (Mesoamerican nephropathy)","volume":"12","author":"Carstens","year":"2023","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13287-017-0557-7","article-title":"Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients","volume":"8","author":"Makhlough","year":"2017","journal-title":"Stem Cell Res Therapy"},{"key":"2026052423463769400_sxag015-B75","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000336028","article-title":"Molecular characterization of the regenerative response induced by intrarenal transplantation of selected renal cells in a rodent model of chronic kidney disease","volume":"196","author":"Genheimer","year":"2012","journal-title":"Cells Tissues Organs"},{"key":"2026052423463769400_sxag015-B76","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1159\/000512586","article-title":"Protocol and baseline data on renal autologous cell therapy injection in adults with chronic kidney disease secondary to congenital anomalies of the kidney and urinary tract","volume":"50","author":"Stavas","year":"2021","journal-title":"Blood Purif"},{"key":"2026052423463769400_sxag015-B77","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1681\/ASN.2016101150","article-title":"Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery","volume":"29","author":"Swaminathan","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B78","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/sctm.20-0561","article-title":"Acute kidney injury successfully treated with autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34-Positive cell transplantation: a first-in-human report","volume":"10","author":"Suzuki","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B79","doi-asserted-by":"publisher","first-page":"e169424","DOI":"10.1172\/jci.insight.169424","article-title":"A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome","volume":"8","author":"Vivarelli","year":"2023","journal-title":"JCI Insight"},{"key":"2026052423463769400_sxag015-B80","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.34067\/KID.0000000000000563","article-title":"Safety and tolerability of adipose-derived mesenchymal stem cell (ADR-001) therapy for IgA nephropathy","volume":"5","author":"Tanaka","year":"2024","journal-title":"Kidney360"},{"key":"2026052423463769400_sxag015-B81","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.21037\/atm-20-2502a","article-title":"Tolerance induction with donor hematopoietic stem cell infusion in kidney transplantation: a single-center experience in China with a 10-year follow-up","volume":"8","author":"Wang","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026052423463769400_sxag015-B82","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3389\/fimmu.2018.01359","article-title":"Long-Term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy","volume":"9","author":"Perico","year":"2018","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B83","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2215\/CJN.04950610","article-title":"Autologous mesenchymal stromal cells and kidney transplantation","volume":"6","author":"Perico","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026052423463769400_sxag015-B84","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/sctm.19-0185","article-title":"Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration","volume":"9","author":"Casiraghi","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B85","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/tri.12132","article-title":"Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation","volume":"26","author":"Perico","year":"2013","journal-title":"Transpl Int"},{"key":"2026052423463769400_sxag015-B86","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/ajt.15910","article-title":"Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: the neptune study, a phase I single-center study","volume":"20","author":"Dreyer","year":"2020","journal-title":"Am J Transpl"},{"key":"2026052423463769400_sxag015-B87","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1111\/ajt.16528","article-title":"Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: the randomized prospective, single-center, open-label TRITON study","volume":"21","author":"Reinders","year":"2021","journal-title":"Am J Transpl"},{"key":"2026052423463769400_sxag015-B88","doi-asserted-by":"publisher","first-page":"1240347","DOI":"10.3389\/fimmu.2023.1240347","article-title":"Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC","volume":"14","author":"Dreyer","year":"2023","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B89","doi-asserted-by":"publisher","first-page":"1455300","DOI":"10.3389\/fimmu.2024.1455300","article-title":"Allogenic MSC infusion in kidney transplantation recipients promotes within 4 hours distinct B cell and T cell phenotypes","volume":"15","author":"Hendriks","year":"2024","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B90","doi-asserted-by":"publisher","first-page":"eaam7828","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026052423463769400_sxag015-B91","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2018.08.046","article-title":"Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study","volume":"95","author":"Erpicum","year":"2019","journal-title":"Kidney Int"},{"key":"2026052423463769400_sxag015-B92","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.18632\/oncotarget.7725","article-title":"Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study","volume":"7","author":"Pan","year":"2016","journal-title":"Oncotarget"},{"key":"2026052423463769400_sxag015-B93","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/TP.0b013e3182754c53","article-title":"Donor-Derived mesenchymal stem cells combined with Low-Dose tacrolimus prevent acute rejection after renal transplantation","volume":"95","author":"Peng","year":"2013","journal-title":"Transplant"},{"key":"2026052423463769400_sxag015-B94","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12967-018-1422-x","article-title":"Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial","volume":"16","author":"Sun","year":"2018","journal-title":"J Transl Med"},{"key":"2026052423463769400_sxag015-B95","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jama.2012.316","article-title":"Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants","volume":"307","author":"Tan","year":"2012","journal-title":"JAMA"},{"key":"2026052423463769400_sxag015-B96","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3109\/0886022X.2014.950931","article-title":"Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation\u2013single center experience","volume":"36","author":"Vanikar","year":"2014","journal-title":"Ren Fail"},{"key":"2026052423463769400_sxag015-B97","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5966\/sctm.2012-0114","article-title":"Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: Results of a phase I study","volume":"2","author":"Reinders","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"2026052423463769400_sxag015-B98","doi-asserted-by":"publisher","first-page":"10772","DOI":"10.3389\/ti.2022.10772","article-title":"Autologous mesenchymal stem cells for treatment of chronic active antibody-mediated kidney graft rejection: report of the phase I\/II clinical trial case series","volume":"35","author":"Ve\u010deri\u0107-Haler","year":"2022","journal-title":"Transpl Int"},{"key":"2026052423463769400_sxag015-B99","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jcyt.2025.05.011","article-title":"Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients","volume":"27","author":"Park","year":"2025","journal-title":"Cytotherapy"},{"key":"2026052423463769400_sxag015-B100","doi-asserted-by":"publisher","first-page":"662441","DOI":"10.3389\/fimmu.2021.662441","article-title":"Efficacy and safety of bone marrow-derived mesenchymal stem cells for chronic antibody-mediated rejection after kidney transplantation- a single-arm, two-dosing-regimen, phase I\/II study","volume":"12","author":"Wei","year":"2021","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B101","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1080\/0886022X.2021.1968432","article-title":"Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study","volume":"43","author":"Zhang","year":"2021","journal-title":"Ren Fail"},{"key":"2026052423463769400_sxag015-B102","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/cells15020196","article-title":"Effects of repeated intravenous injections of autologous adipose-derived mesenchymal stromal cells expressing an allogeneic MHC protein in a mouse model of diabetic nephropathy","volume":"15","author":"Li","year":"2026","journal-title":"Cells"},{"key":"2026052423463769400_sxag015-B103","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/imcb.12024","article-title":"Anti-donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells","volume":"96","author":"Alagesan","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"2026052423463769400_sxag015-B104","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13287-017-0742-8","article-title":"Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells","volume":"8","author":"Berglund","year":"2017","journal-title":"Stem Cell Res Ther."},{"key":"2026052423463769400_sxag015-B105","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"2026052423463769400_sxag015-B106","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/dvdy.22","article-title":"Kidney organoids in translational medicine: disease modeling and regenerative medicine","volume":"249","author":"Miyoshi","year":"2020","journal-title":"Dev Dyn"},{"key":"2026052423463769400_sxag015-B107","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2026052423463769400_sxag015-B108","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/hum.2023.186","article-title":"A review of the cost-effectiveness evidence for FDA-approved cell and gene therapies","volume":"35","author":"Abuloha","year":"2024","journal-title":"Hum Gene Ther"},{"key":"2026052423463769400_sxag015-B109","doi-asserted-by":"publisher","first-page":"e0274136","DOI":"10.1371\/journal.pone.0274136","article-title":"Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: a cost-effectiveness analysis","volume":"17","author":"Barry","year":"2022","journal-title":"PLoS One"},{"key":"2026052423463769400_sxag015-B110","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.1111\/jcmm.15250","article-title":"Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs-mediated CD8+ T cell responses","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2026052423463769400_sxag015-B111","doi-asserted-by":"publisher","first-page":"684197","DOI":"10.3389\/fimmu.2021.684197","article-title":"Mesenchymal stem cell protects injured renal tubular epithelial cells by regulating mTOR-Mediated Th17\/Treg axis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Immunol"},{"key":"2026052423463769400_sxag015-B112","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1152\/physiolgenomics.00103.2022","article-title":"Bone marrow mesenchymal stem cells repress renal transplant immune rejection by facilitating the APRIL phosphorylation to induce regulation B cell production","volume":"55","author":"Xie","year":"2023","journal-title":"Physiol Genomics"},{"key":"2026052423463769400_sxag015-B113","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1042\/ETLS20190091","article-title":"Synthetic biology for improving cell fate decisions and tissue engineering outcomes","volume":"3","author":"Vogel","year":"2019","journal-title":"Emerg Top Life Sci"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stmcls\/advance-article-pdf\/doi\/10.1093\/stmcls\/sxag015\/67631386\/sxag015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/44\/6\/sxag015\/67631386\/sxag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/44\/6\/sxag015\/67631386\/sxag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:46:45Z","timestamp":1779680805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/doi\/10.1093\/stmcls\/sxag015\/8554173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/stmcls\/sxag015","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,28]]},"article-number":"sxag015"}}